Physician profile
Ruby Favela-Prezas
NPI 1134466774
$3,632.43
in general payments reported to CMS, 2019-2025
21 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $530 · 2022: $508 · 2023: $739 · 2024: $622 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,594.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,820.94 | 2021-2025 | Sogroya, Wegovy, Norditropin |
| Beta Bionics, INC. | $214.43 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tolmar, INC. | $175.70 | 2023-2025 | Fensolvi |
| Dexcom, INC. | $174.55 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Soleno Therapeutics, INC. | $172.45 | 2025 | Vykat Xr |
| Ascendis Pharma Endocrinology INC | $157.24 | 2024-2025 | Skytrofa |
| Sanofi-Aventis U.S. LLC | $145.39 | 2025 | |
| Kyowa Kirin, INC. | $143.73 | 2023-2025 | Crysvita |
| Abbott Laboratories | $136.86 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $85.48 | 2021 | |
| Tandem Diabetes Care, INC. | $69.48 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $62.10 | 2025 | |
| Azurity Pharmaceuticals, INC. | $60.42 | 2024-2025 | Triptodur |
| Eton Pharmaceuticals, INC. | $42.66 | 2025 | Increlex, Khindivi, Alkindi |
| Amphastar Pharmaceuticals, INC. | $40.32 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $30.96 | 2022 | |
| Abbvie INC. | $23.49 | 2025 | |
| Neurocrine Biosciences, INC. | $22.19 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.95 | 2021 | |
| Ibsa Pharma INC. | $17.84 | 2024 | Tirosint, Licart |
| Medtronic, INC. | $16.25 | 2025 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Favela-Prezas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.